Doc - I find the tissue agnostic description to be the most intriguing thus far, obviously as a strategic advantage for DCVAX if granted. But after giving it further thought, I also see it as a practical matter from a regulator's point of view. With so many combos under evaluation, and new modality arrivals, practitioners could suffer having choice anxiety. Where picking and choosing becomes a new skill to learn, where personalization turns burdensome due to the learning curve involved. A systematically broad agnostic designation would translate into faster adaption rates and present a far less convoluted approach. I can definitely see the task of pursuing combos to be easier in practice with a foundation from which to personalize treatments. IMHO.
ILT
Market Data 
Markets 
AI
